The congenital diaphragmatic hernia drugs market size is expected to see strong growth in the next few years. It will grow to $5.84 billion in 2028 at a compound annual growth rate (CAGR) of 7.5%. The growth in the forecast period can be attributed to growing healthcare expenditure, rare disease incentives, growing patient advocacy groups, regenerative medicine, targeted therapies. Major trends in the forecast period include advancements in medical research, advancements in drug development, advances in fetal surgery, pharmacological lung growth, increasing use of personalized medicine, development of new and innovative drug delivery systems, digital health technologies.
To access more details regarding this report, visit the link:
https://www.thebusinessresearchcompany.com/report/congenital-diaphragmatic-hernia-drugs-global-market-report
Segmentation & Regional Insights
The congenital diaphragmatic hernia drugs market covered in this report is segmented –
1) By Type: Posterolateral Bochdalek Hernia; Anterior Morgagni Hernia; Hiatal Hernia
2) By Treatment: Extracorporeal Membrane Oxygenation; Other Treatments
3) By Diagnosis: Prenatal; Postnatal
4) By End-User: Hospitals; Homecare; Specialty Clinics; Other End Users
North America was the largest region in the congenital diaphragmatic hernia drugs market in 2023. The regions covered in congenital diaphragmatic hernia drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
Intrigued to explore the contents? Secure your hands-on sample copy of the report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=12928&type=smp
Major Driver Impacting Market Growth
The rising birth defects rate is expected to propel the growth of the congenital diaphragmatic hernia drug market. Birth defects refer to structural or functional abnormalities present at birth that can affect the baby’s overall health and development. The treatment for congenital diaphragmatic hernia provides prenatal screening, genetic counseling and targeted therapies that lower the occurrence of birth defects due to congenital diaphragmatic hernia and improve the potential for early intervention and personalized care, enhancing the overall well-being and quality of life of affected individuals. For instance, in March 2023, according to the World Health Organization (WHO), a US-based intergovernmental organization, annually, approximately 8 million infants are born with birth defects, with low- and middle-income nations accounting for 9 out of 10 significant problems. Further, an estimated 240,000 newborns die worldwide within 28 days of birth each year due to congenital disorders. Therefore, the rising birth defect rate drives the congenital diaphragmatic hernia drug market.
Key Industry Players
Major players in the congenital diaphragmatic hernia drugs market are Pfizer Inc., Johnson and Johnson Limited, Merck and Co. Inc., AbbVie Inc., Novartis AG, GlaxoSmithKline PLC, Medtronic PLC, Amgen Inc., Becton, Dickinson and Company, Viatris Inc., B. Braun SE, Sun Pharmaceutical Industries Ltd., C.R. Bard Inc., W. L. Gore & Associates, Chiesi Farmaceutici S.p.A., Getinge AB, Ferring Pharmaceuticals, Mallinckrodt Pharmaceuticals, Integra LifeSciences Corporation, Genentech Inc., LifeCell International Private Limited, Cook Biotech Inc., Cousin Biotech SAS, Dipro Medical Devices S.R.L., Aspide Medical.
The congenital diaphragmatic hernia drugs market report table of contents includes:
- Executive Summary
- Congenital Diaphragmatic Hernia Drugs MarketCharacteristics
- Congenital Diaphragmatic Hernia Drugs MarketTrends And Strategies
- Congenital Diaphragmatic Hernia Drugs Market- Macro Economic Scenario
- Global Congenital Diaphragmatic Hernia Drugs MarketSize and Growth
.
.
.
- Global Congenital Diaphragmatic Hernia Drugs MarketCompetitive Benchmarking
- Global Congenital Diaphragmatic Hernia Drugs MarketCompetitive Dashboard
- Key Mergers And Acquisitions In Congenital Diaphragmatic Hernia Drugs Market
- Congenital Diaphragmatic Hernia Drugs MarketFuture Outlook and Potential Analysis
- Appendix
Top Major Players :
- Pfizer Inc.
- Johnson and Johnson Limited
- Merck and Co. Inc.
- AbbVie Inc.
- Novartis AG
Explore the trending research reports from TBRC:
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: [email protected]
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
